RJA
TERN

Raymond James & Associates’s Terns Pharmaceuticals TERN Stock Holding History

Raymond James & Associates’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,488
Closed -$127K – 4070
2022
Q4 		$127K Buy
+12,488
New +$83.1K ﹤0.01% 3586

Other funds holding TERN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Raymond James & Associates's TERN Position: Q1 2023 in Review

Raymond James & Associates sold out of Terns Pharmaceuticals (TERN) in Q1 2023, closing a stake of 12,488 shares — an estimated $127K sold.

Raymond James & Associates first reported a position in TERN in Q4 2022 and held it in 1 quarter. The position peaked at $127K in Q4 2022. 78 funds tracked by Wall St. Rank hold TERN as of Q1 2023.

  • Raymond James & Associates reported no remaining Terns Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 12,488 Terns Pharmaceuticals shares in Q1 2023, an estimated $127K.
  • Raymond James & Associates first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Raymond James & Associates's Terns Pharmaceuticals position peaked at $127K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.